13.49

3.30% -0.46

Cullinan Therapeutics Inc (CGEM)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$13.95

Aprire:

$14.08

Volume 24 ore:

707.37K

Relative Volume:

0.82

Capitalizzazione di mercato:

$796.94M

Reddito:

Utile/perdita netta:

$-219.88M

Rapporto P/E:

-3.6226

EPS:

-3.7238

Flusso di cassa netto:

$-175.76M

1 W Prestazione:

-14.29%

1M Prestazione:

+16.39%

6M Prestazione:

+106.58%

1 anno Prestazione:

+51.23%

Intervallo 1D:

$13.12

$14.28

Intervallo di 1 settimana:

$13.12

$16.49

Portata 52W:

$5.68

$16.74

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Nome

Cullinan Therapeutics Inc

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

617-410-4650

Indirizzo

ONE MAIN STREET, CAMBRIDGE

Dipendente

111

Cinguettio

Prossima data di guadagno

2026-03-12

Ultimi documenti SEC

CGEM's Discussions on Twitter

Compare CGEM vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CGEM Cullinan Therapeutics Inc	13.49	796.94M	0	-219.88M	-175.76M	-3.7238
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-17	Iniziato	Citigroup	Buy
2026-02-02	Iniziato	Guggenheim	Buy
2025-08-21	Ripresa	H.C. Wainwright	Buy
2025-06-11	Ripresa	Stifel	Buy
2024-10-24	Iniziato	UBS	Buy
2024-05-01	Iniziato	Stifel	Buy
2024-04-15	Iniziato	William Blair	Outperform
2024-02-15	Iniziato	Wedbush	Outperform
2023-06-15	Iniziato	TD Cowen	Outperform
2022-11-21	Iniziato	BTIG Research	Buy
2021-04-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2021-02-02	Iniziato	Evercore ISI	Outperform
2021-02-02	Iniziato	Morgan Stanley	Equal-Weight
2021-02-02	Iniziato	SVB Leerink	Outperform
2021-02-01	Iniziato	H.C. Wainwright	Buy

Mostra tutto

Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie

Mar 14, 2026

Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data - MarketBeat

Mar 14, 2026

Mar 12, 2026

Whale Trades: Can Cullinan Therapeutics Inc outperform under higher oil pricesDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn

Mar 12, 2026

CGEM Earnings History & Surprises | EPS & Revenue Results | CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) - ChartMill

Mar 12, 2026

Mar 11, 2026

Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) - The Globe and Mail

Mar 11, 2026

Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat

Mar 11, 2026

Cullinan Therapeutics (CGEM): Wedbush Raises Price Target to $36 - GuruFocus

Mar 11, 2026

Cullinan Therapeutics Flags 2026 as Key Year for Clinical Data - Intellectia AI

Mar 11, 2026

Mar 10, 2026

CGEM: Key T-cell engager programs advance toward pivotal milestones and data readouts in 2026 - TradingView

Mar 10, 2026

Cullinan Therapeutics: Q4 Earnings InsightsCullinan Therapeutics (NASDAQ:CGEM) - Benzinga

Mar 10, 2026

Cullinan Oncology (CGEM) Projects Strong Cash Position into 2029 - GuruFocus

Mar 10, 2026

Cullinan Therapeutics Reports 2025 Financial Results, Updates on CLN-978, Zipalertinib NDA, and 2026 Clinical Milestones - Minichart

Mar 10, 2026

Stifel raises Cullinan Oncology stock price target on autoimmune progress By Investing.com - Investing.com South Africa

Mar 10, 2026